Boston, MA
Joined July 2013
- Tweets863
- Following441
- Followers4.5K
- Likes3K
Ann Partridge MD, MPH retweeted
Dr. Erica Mayer (@elmayermd) at the #ESMO26 HR+ breast cancer poster session showcasing a recent expert consensus on the management of ribociclib-associated liver-related adverse events in HR+/HER2− #BreastCancer.
Ann Partridge MD, MPH retweeted
Dr. Sara Tolaney (@stolaney1) in the #ESMO26 poster session on HR+ #BreastCancer, sharing work on Gedatolisib vs other regimens post-CDK4/6i and endocrine therapy in #PIK3CA wild-type HR+/ HER2- advanced breast cancer.
Ann Partridge MD, MPH retweeted
Noa Waisman presenting our work at the 2026 ASCO Quality Care Symposium exploring in person vs virtual recruitment for oncology clinical trials (proud mentor moment!) #ASCOQLTY @AnnPartridgeMD @DrKateDibble
Ann Partridge MD, MPH retweeted
October is #BreastCancerAwarenessMonth. A time to reflect, learn, and lead in survivorship care. Check out @harvardmed’s CME course, Updates to #CancerSurvivorship: Optimizing Care and Outcomes.
📚 Course Highlights:
• Deepen your understanding of survivorship in breast cancer and beyond
• Address long-term medical & psychosocial needs of survivors
• Apply evidence-based tools to improve care delivery & coordination
Register Here! learn.hms.harvard.edu/progra…
Ann Partridge MD, MPH retweeted
A huge congratulations to @elmayermd and team on the publication of evERA in @NEJM!
Hoping we get approval for giredestrant + everolimus in the near future -- this would be wonderful for our patients with HR+ MBC!
nejm.org/do/10.1056/NEJMdo00…
@DFCI_BreastOnc
Sign up now and join us for this in person event!
Join Dr. Ann Partridge (@AnnPartridgeMD) and the Young & Strong community for a day of support, education, and connection at the 2026 Young & Strong Forum.
Hear from breast cancer experts, connect with others who understand, and explore topics relevant to young adults living with breast cancer.
📅 Friday, October 30 | 8:30 a.m.–5:30 p.m.
📍 InterContinental Boston
🎟️ Free to attend
Register today!
youngandstrong.dana-farber.o…
Ann Partridge MD, MPH retweeted
🎙️Tune in to hear Dr. Sara Tolaney (@stolaney1) discuss new first-line treatment options for metastatic triple-negative breast cancer on the Patient From Hell podcast.
#mTNBC #TNBC #BreastCancer #MBC
Watch on YouTube:
youtube.com/watch?v=ZWjfSTBQ…
Listen on Spotify:
open.spotify.com/episode/4H4…
Ann Partridge MD, MPH retweeted
In today’s @BostonGlobe @DanaFarber’s @AnnPartridgeMD discusses how more cancer survivors are able to realize their dream of having a baby and growing their family thanks to persistent research and new technology. ➡️bit.ly/3TLxx5L
Ann Partridge MD, MPH retweeted
Check out this recent paper 👉A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
🔓pubmed.ncbi.nlm.nih.gov/4205…
✍️@ChowdhuryLab @bdcrompton @NarjustFlorezMD @judygarber5 @IrenemGhobrial @ctdnaMD @ASCOPres @AnnPartridgeMD @sands_jacob @SookbinWoo @g_parmigiani @TimRebbeck @SapnaSyngal @CEBP_AACR
Ann Partridge MD, MPH retweeted
The day before the @PanMass !
Riding 162 miles to raise funds for Cancer research! With @AnnPartridgeMD @bunnell_craig @BradMcG04 @MikeSerzanMD and 1st rime rider @DrPrateekKhanna! #PMC2026
Link to donate: profile.pmc.org/TC0306
@OncoAlert
Ann Partridge MD, MPH retweeted
New resource for young adults with #BreastCancer!
Support your younger breast cancer patients with Young and Strong, a resource website for those diagnosed under 45. It offers trusted guidance through diagnosis, treatment, and survivorship, plus practical, searchable tools to meet individual needs.
➡️ youngandstrong.dana-farber.o…
@AnnPartridgeMD @VarellaLeticia1 @PhilipPoorvu
#AYA #AYAcancer #AYAware #YoungAdultCancer
Ann Partridge MD, MPH retweeted
Congratulations to @amarkelkar for his recent election to the @AmerMedicalAssn Board of Trustees. His focus on prior authorization reform, combatting critical drug shortages, ensuring research funding as well as inclusivity and diversity, and protecting broad access to care will support patients at Dana-Farber and beyond. ⬇️ bit.ly/3QwEBSx
Ann Partridge MD, MPH retweeted
“There’s a two-way street here. Having these teams and connections going from bench to bedside, back to bench and such, I think will speed up our ability to help patients,” F. Stephen Hodi, a Harvard Medical School professor of medicine at Dana-Farber, said about the collaboration behind cancer research and care.
Read more about how basic scientists, translational scientists, and clinical medical researchers joined forces to develop a cancer vaccine. ⬇️ bit.ly/4pazCUt
Ann Partridge MD, MPH retweeted
📣 Just out in @Annals_Oncology our editorial on the AMH in RxPONDER
❌ At present, no clinical utility of AMH
We shared our thoughts on ovarian reserve to tailor adj tx in premenop pts with HR+ eBC
- with @AnnPartridgeMD
@harvardmed @harvardmed @DFCI_BreastOnc @DanaFarber
#ASCO26 - beautiful moment of long-awaited celebration and hope!
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
Ann Partridge MD, MPH retweeted
Niece article @ValenzaCarmine @stolaney1 @DFCI_BreastOnc Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10.120…
Ann Partridge MD, MPH retweeted
🆕 Results from the POSITIVE trial with longer term follow-up are now out in @Annals_Oncology
Temporary interruption of endocrine therapy to attempt pregnancy is safe and does not increase the risk of #breastcancer events @AnnPartridgeMD
doi.org/10.1016/j.annonc.202…
Ann Partridge MD, MPH retweeted
Elinzanetant (NK1/NK3 antagonist)
OASIS-4: rapid/sustained improvement in VMS
Subgroup analysis on impact on sleep disturbance and QOL by type of endocrine tx
n=474
Benefit seen irrespective of type of endocrine therapy
@OncoAlert #ASCO26
Ann Partridge MD, MPH retweeted
Feeling incredibly fortunate to have the chance to volunteer for @ASCO and join an insightful panel with @AnnPartridgeMD, @BourlonMaite and @HundalJasmin on “Finding Your Niche in Oncology” 🎯 #ASCO26
